Loss of 50% of excess weight using a very low energy diet improves insulin-stimulated glucose disposal and skeletal muscle insulin signalling in obese insulin-treated type 2 diabetic patients
- First Online:
- Cite this article as:
- Jazet, I.M., Schaart, G., Gastaldelli, A. et al. Diabetologia (2008) 51: 309. doi:10.1007/s00125-007-0862-2
- 688 Downloads
Both energy restriction (ER) per se and weight loss improve glucose metabolism in obese insulin-treated type 2 diabetic patients. Short-term ER decreases basal endogenous glucose production (EGP) but not glucose disposal. In contrast the blood glucose-lowering mechanism of long-term ER with substantial weight loss has not been fully elucidated. The aim of this study was to investigate the effect of loss of 50% of excess weight [50% excess weight reduction (EWR)] on EGP, whole-body insulin sensitivity and the disturbed myocellular insulin-signalling pathway in ten obese insulin-treated type 2 diabetic patients.
A euglycaemic–hyperinsulinaemic clamp with stable isotopes ([6,6-2H2]glucose and [2H5]glycerol) combined with skeletal muscle biopsies was performed during a very low energy diet (VLED; 1,883 kJ/day) on day 2 and again after 50% EWR. Oral blood glucose-lowering agents and insulin were discontinued 3 weeks prior to the VLED and at the start of the VLED, respectively.
Loss of 50% EWR (20.3 ± 2.2 kg from day 2 to day of 50% EWR) normalised basal EGP and improved insulin sensitivity, especially insulin-stimulated glucose disposal (18.8 ± 2.0 to 39.1 ± 2.8 μmol kg fat-free mass−1 min−1, p = 0.001). The latter was accompanied by improved insulin signalling at the level of the recently discovered protein kinase B/Akt substrates AS160 and PRAS40 along with a decrease in intramyocellular lipid (IMCL) content.
Considerable weight loss in obese, insulin-treated type 2 diabetic patients normalises basal EGP and improves insulin sensitivity resulting from an improvement in insulin signal transduction in skeletal muscle. The decrease in IMCL might contribute to this effect.
KeywordsHyperinsulinaemic–euglycaemic clamp Insulin resistance Insulin signalling Muscle biopsy Obesity Type 2 diabetes Very low calorie diet Very low energy diet Weight loss
Akt substrate of 160 kDa
endogenous glucose production
excess weight reduction
fatty acid transporter (homologue to human CD36)
hepatic insulin resistance index
metabolic clearance rate of insulin
protein kinase B/Akt
proline-rich Akt substrate of 40 kDa
rate of appearance
rate of disappearance
very low energy diet
Insulin resistance is of pivotal clinical importance in obese patients with type 2 diabetes mellitus. Because more than 70% of insulin-stimulated glucose transport occurs in skeletal muscle , skeletal muscle insulin resistance contributes substantially to the metabolic derangements seen in these patients.
In type 2 diabetic patients the impairment in insulin-stimulated glucose disposal is due to defects in the insulin-signalling pathway regulating the translocation of GLUT-4 to the cell membrane. Notably, defects in insulin-induced phosphorylation of IRS-1 and phosphatidylinositol 3-kinase (PI3K) [2, 3, 4] and in translocation of GLUT-4 to the cell membrane [5, 6] have been found in skeletal muscle of patients with type 2 diabetes, whereas, in contrast, total GLUT-4 protein and mRNA levels have repeatedly been shown to be normal [7, 8]. The involvement of the PI3K substrate protein kinase B/Akt (PKB/Akt) in skeletal muscle insulin resistance is less clear, illustrated by studies reporting either normal [3, 9] or impaired activation [10, 11] by insulin. However, the recently characterised Akt substrate 160 (AS160) [12, 13] has been implicated in the link between PKB/Akt activation and GLUT-4 trafficking ; also, insulin-mediated AS160 phosphorylation is impaired in skeletal muscle of type 2 diabetic patients . Collectively these studies highlight the importance of the PI3K–PKB/Akt–AS160-signalling pathway regulating GLUT-4 trafficking.
Energy restriction (ER) and weight loss both improve hyperglycaemia in type 2 diabetic patients. We previously reported that a 2 day very low energy diet [VLED, 1,883 kJ (450 kcal)/day] decreased basal endogenous glucose production (EGP) in obese insulin-treated type 2 diabetic patients in whom all blood glucose-lowering medication was discontinued . These changes were accompanied neither by an improvement in whole-body peripheral insulin sensitivity nor by changes in insulin signalling, fuel transporter [GLUT-4 and fatty acid transporter homologue to human CD36 (FAT/CD 36)] content and localisation and triacylglycerol content in skeletal muscle .
In the present study, we assessed whether a prolonged VLED in obese insulin-treated type 2 diabetic patients leading to substantial weight loss (50% of excess weight) has a different blood glucose-lowering mechanism compared with ER alone (2 day VLED).
Patient characteristics and body composition parameters before and after 2 days of a VLED and again at 50% EWR with the VLED
Day 2 VLED
55 ± 3
40.2 ± 1.6
39.7 ± 1.7b
32.3 ± 1.2d
113.0 ± 7.1
110.9 ± 6.9c
90.6 ± 0.5d
51.0 ± 3.9
50.1 ± 3.7
32.7 ± 3.0d
Waist circumference (cm)
126.8 ± 3.3
126.2 ± 3.5
107.7 ± 3.3d
Fasting plasma glucose (mmol/l)
11.1 ± 0.8
12.5 ± 0.5
7.8 ± 0.5d
(HbA1c 7.7 ± 0.4%)
329 ± 11
283 ± 12e
Fasting serum insulin (pmol/l)
168 ± 2.2
106 ± 9f
Units of insulin (U/day)
94 ± 14
Patients had to use at least 30 U insulin/day (mean 94 ± 14 U/day; eight patients also used metformin and two patients used rosiglitazone with the insulin therapy) and had to have a BMI > 30 kg/m2. In addition, patients had to have remaining endogenous insulin secretion defined as a fasting plasma C-peptide level >0.27 nmol/l or a twofold increase of the basal C-peptide level after administration of 1 mg glucagon i.v.
Patients also had to have stable bodyweight for at least 3 months and were instructed not to alter lifestyle habits from screening until the start of the study.
Diet and protocol outline
During the VLED patients visited the research centre weekly for support to keep up with their diet, confirmation of compliance and measurement of bodyweight, WHR, blood pressure and blood glucose regulation. No blood glucose-lowering agents were used during this period.
Assessments of body composition
On both study days, body fat mass (FM) and fat-free mass (FFM) were measured by bioelectrical impedance analysis (Bodystat 1500; Bodystat, Douglas, Isle of Man, UK).
Length (m) and weight (kg), BMI and waist circumference were measured according to WHO recommendations.
Metabolic studies were performed as described previously . In short, basal rates of glucose and glycerol turnover were assessed after 3 h of an adjusted primed [17.6 μmol/kg × actual plasma glucose concentration (mmol/l)/5 (normal plasma glucose)] continuous (0.33 μmol kg−1 min−1) infusion of [6,6-2H2]glucose (enrichment 99.9%; Cambridge Isotopes, Cambridge, MA, USA) and 1.5 h of a primed (1.6 μmol/kg) continuous (0.11 μmol kg−1 min−1) infusion of [2H5]glycerol (Cambridge Isotopes). Subsequently, insulin-stimulated rates of glucose and glycerol turnover were measured after 4.5 h of a hyperinsulinaemic–euglycaemic clamp (Actrapid; Novo Nordisk Pharma, Alphen aan de Rijn, the Netherlands; rate 40 mU m−2 min−1). Glucose values were clamped at 5 mmol/l via the infusion of a variable rate of 20% glucose enriched with 3% [6,6-2H2]glucose.
Basal and insulin-stimulated glucose and lipid oxidation rates  were determined by indirect calorimetry with a ventilated hood (Oxycon Beta; Mijnhardt Jaegher, Breda, the Netherlands).
Serum insulin was measured with an immunoradiometric assay (Biosource, Nivelles, Belgium). Serum C-peptide and glucagon levels were measured with an RIA from Linco Research (St Charles, MO, USA). Growth hormone was measured with a time-resolved immunofluorescent assay (Wallac, Turku, Finland) specific for the 22 kDa growth hormone. Cortisol was measured with an RIA (Sorin Biomedica, Milan, Italy). Serum triacylglycerol was measured with a fully automated Modular P 800 and fructosamine with a Modular I 800 system, both from Hitachi (Tokyo, Japan).
Serum NEFAs were measured using the enzymatic colorimetric acyl-CoA synthase/acyl-CoA oxidase assay (Wako Chemicals, Neuss, Germany). Serum glucose and [6,6-2H2]glucose as well as serum glycerol and [2H5]glycerol were determined in a single analytical run, using GC-MS as described previously .
Muscle biopsies were taken from the vastus lateralis muscle in the basal situation and 30 min after the start of the insulin infusion [17, 20] using a modified Bergström needle under localised anaesthesia with 1% lidocaine. Muscle samples were snap-frozen in liquid nitrogen-cooled isopentane and stored at −80°C until further analysis.
Muscle biopsies were homogenised in PI3K lysis buffer using an Ultraturrax mixer and centrifuged (15 min; 16,100×g; 4°C), then protein content was determined using a BCA kit (Pierce, Rockford, IL, USA) . IRS-1 was immunoprecipitated overnight (4°C) from 1.5 mg protein using IRS-1 antibody K6, and PI3K activity was determined as described previously .
In addition, proteins (25 μg per lane) were separated by SDS-PAGE and blotted on polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). Filters were incubated overnight (4°C) with IRS-1 K6 and Akt-1 antibody (Upstate, Lake Placid, NY, USA), anti-phospho-proline rich Akt substrate 40-Thr246 (#44-100G), anti-phospho-AS160 (#44-1071G) (Biosource International, Camarillo, CA, USA) and anti-AS160/TBC1D4 antibody (Abcam, Cambridge, UK). Bound antibodies were detected using appropriate horseradish peroxidase-conjugated secondary antibodies (Promega, Madison, WI, USA) at a 1:10,000 dilution, followed by visualisation by enhanced chemiluminescence. Blots were quantified by densitometric analysis of the films using Scion Image beta 4.02 software (Scion, Frederick, MD, USA).
Oil Red O staining
Tissue sections of basal biopsies were stained with Oil Red O combined with a double-immunofluorescence assay (anti-laminin and a monoclonal antibody raised against adult human slow myosin heavy chain) to allow quantification of intramyocellular lipids (IMCLs) as described before .
Oil Red O epifluorescence signal was quantified for each muscle cell of each cross section. Lipid droplet density was calculated by dividing the total number of droplets by the total IMCL area measured .
Western blotting for FAT/CD36 and GLUT-4
For Western blotting analyses, muscle membrane fractions and total muscle protein fractions were prepared as described before for GLUT-4  and fatty acid transporter homologue to human CD36 (FAT/CD36) [17, 24] in biopsies taken during the insulin-stimulated situation.
Blots were incubated with the polyclonal GLUT-4-BW antibody  or the MO25 monoclonal antibody specific for FAT/CD36 . Protein bands were detected and quantified with an Odyssey Infrared Imager (Li-Cor Biosciences, Westburg BV, Leusden, The Netherlands).
A physiological and isotopic steady-state was achieved during the last 30 min of the basal period and the insulin-infusion period, therefore the rates of appearance (Ra) and disappearance (Rd) for glucose and glycerol were calculated as the tracer infusion rate divided by the tracer-to-tracee ratio . Glucose flux rates were expressed per kg FFM, whereas glycerol flux rates were normalised per kg FM.
EGP during the basal steady-state is equal to the Ra of glucose, whereas EGP during the clamp was calculated as the difference between Ra and the glucose infusion rate. Since the fasting plasma insulin concentration is a strong inhibitory stimulus for EGP, the basal hepatic insulin resistance index (HIR) (μmol min−1 kgFFM−1 pmol−1 × l) was calculated as the product of fasting EGP and fasting plasma insulin concentration. Experimental validation for the use of this index has been published [26, 27]. The metabolic clearance rate of insulin (MCRI) was calculated as the constant infusion rate of insulin divided by the steady-state serum insulin concentration corrected for endogenous insulin secretion .
Total lipid and carbohydrate oxidation rates were calculated as described by Simonson and DeFronzo . Non-oxidative glucose metabolism was calculated by subtracting the glucose oxidation rate (determined by indirect calorimetry) from glucose Rd.
Percentage excess weight was calculated as: 100 × (weight/ideal bodyweight) − 100. Ideal bodyweight for height was determined according to the 1983 Metropolitan Life Insurance tables (Metropolitan Life Insurance Company, New York, USA).
Data are presented as means±SEM. Differences between day 2 and day of 50% EWR, as well as differences between basal and insulin-stimulated biopsies were analysed by the Student’s t test for paired samples. Non-parametric (Wilcoxon signed-rank test) tests for paired samples were performed when appropriate. Correlation analysis was carried out using Pearson’s correlation. All analyses were performed using SPSS for Windows version 12.0 (SPSS, Chicago, IL, USA). Significance was accepted at p < 0.05.
Weight and body composition
Weight loss during the first 2 days (day 0 to day 2) was −2.1 ± 0.3 kg. From day 2 until the second study day, patients lost an additional 20.3 ± 2.2 kg (p = 0.0001), 85% of which was FM (Table 1). BMI decreased from 39.7 ± 1.7 kg/m2 on day 2 to 32.3 ± 1.2 kg/m2 on the day of 50% EWR (p = 0.0001). Mean time to 50% EWR was 17 weeks (range 4–35 weeks). The duration of time to 50% EWR was strongly and significantly positively correlated with bodyweight and body FM on day 0. There was no relationship between time to 50% EWR and any measure of insulin sensitivity or change in insulin sensitivity.
Fasting plasma glucose and insulin concentration
Fasting plasma glucose levels dropped significantly from day 2 to day of 50% EWR (12.5 ± 0.5 to 7.8 ± 0.5 mmol/l, p = 0.0001), as did serum insulin concentrations (from 168 ± 15 to 106 ± 9 pmol/l, p = 0.001).
Serum fructosamine levels declined from 329 ± 11 to 283 ± 12 nmol/l (p = 0.035; Table 1).
EGP and whole-body glucose disposal
Metabolic parameters during a VLED on day 2 and at 50% EWR
Day of 50% EWR
Glucose Rd (μmol kgFFM−1 min−1)
20.0 ± 0.9
18.8 ± 2.0
16.4 ± 1.2c
39.1 ± 2.8c
Glucose Ox (μmol kgFFM−1 min−1)
6.7 ± 1.4
6.1 ± 0.9
4.2 ± 0.4
12.7 ± 1.5b
NOGD (μmol kgFFM−1 min−1)
14.8 ± 1.1
12.2 ± 1.6
12.4 ± 1.1a
27.7 ± 2.8b
EGP (μmol kgFFM−1 min−1)
20.0 ± 0.9
8.5 ± 0.9
16.4 ± 1.2c
4.6 ± 1.2b
HIR (μmol kgFFM−1 min−1 pmol−1 × l)
3,319 ± 245
5,251 ± 500
1,729 ± 193d
2,511 ± 633c
Glycerol Ra (μmol kgFM−1 min−1)
16.4 ± 2.3
11.5 ± 2.3
14.6 ± 1.4
7.5 ± 1.6
Lipid Ox (μmol kgFFM−1 min−1)
8.0 ± 0.5
8.3 ± 0.3
7.1 ± 0.5
5.5 ± 0.8c
MCRI (ml m−2 min−1)
0.47 ± 0.02
0.53 ± 0.03a
12.5 ± 0.5
5.1 ± 0.3
7.8 ± 0.5d
5.4 ± 0.3
Plasma insulin (pmol/l)
168 ± 15
626 ± 23
106 ± 9c
561 ± 28a
150 ± 15
114 ± 18
108 ± 12c
65 ± 12a
1.6 ± 0.2
1.1 ± 0.3
1.2 ± 0.1a
0.3 ± 0.1a
2.7 ± 0.5
2.5 ± 0.5
1.2 ± 0.1c
0.9 ± 0.1a
451 ± 30
404 ± 49
419 ± 34
232 ± 31b
63.2 ± 8.3
86.6 ± 15.0
70.7 ± 5.1
38.9 ± 2.7
Growth hormone (mU/l)
1.2 ± 0.4
4.0 ± 1.5
3.7 ± 1.5
2.4 ± 0.9
Basal EGP decreased ∼20% from day 2 to the day of 50% EWR and insulin suppression of EGP also was significantly stronger on the day of 50% EWR in absolute terms. Consequently, the HIR was significantly lower on the day of 50% EWR than on day 2 under both basal and insulinised conditions (Table 2).
Of the hormones involved in the regulation of EGP, fasting serum cortisol and glucagon concentrations did not change with weight loss, whereas fasting growth hormone levels increased as expected (Table 2).
Insulin-stimulated glucose disposal increased 107% from day 2 to the day of 50% EWR. If we correct for the difference in clamp serum insulin levels between study days by dividing glucose Rd by the clamp serum insulin levels, the difference in peripheral insulin sensitivity between study days becomes even more significant (0.03 vs 0.07 μmol min−1 kgFFM−1 pmol−1 × l, p = 0.0001).
Glycerol Ra and NEFAs, glycerol and triacylglycerol
Basal glycerol Ra decreased by 35% between study days. Exogenous insulin failed to suppress glycerol Ra on day 2 but did so on the day of 50% EWR, to levels that were significantly different from day 2 (Table 2). Accordingly, fasting levels of NEFAs, triacylglycerol and glycerol declined significantly, and clamp values of serum NEFA and glycerol all declined between study days both in the fasting state and in response to euglycaemic hyperinsulinaemia, reflecting a better suppressibility of lipolysis by insulin (Table 2).
Glucose and lipid oxidation rates
On the day of 50% EWR, insulin infusion increased the rate of glucose oxidation significantly compared with day 2. Basal as well as insulin-stimulated non-oxidative glucose disposal also increased significantly after weight loss. The ability of insulin to suppress lipid oxidation was improved with weight loss (Table 2).
Insulin signalling in skeletal muscle biopsies
Activity levels of measured insulin-signalling molecules
Day of 50% EWR
IRS-1-associated PI3K activity
21.7 ± 3.3
28.9 ± 3.0
18.4 ± 2.4
29.9 ± 2.5
15.4 ± 1.7
27.1 ± 2.0
23.6 ± 2.6a
39.0 ± 4.0a
9.0 ± 1.1
23.7 ± 4.2
14.4 ± 2.4b
52.9 ± 5.4c
Effect of weight loss on the fuel transporters GLUT-4 and FAT/CD36
IMCL content as assessed with an Oil Red O staining
Compared with short-term ER (2 day VLED), which only affects basal EGP [16, 17], long-term ER leading to 50% EWR reduced basal EGP and improved insulin sensitivity of the liver, adipose tissue and skeletal muscle in obese, insulin-treated type 2 diabetic patients. These effects occurred despite the fact that patients had been taken off all blood glucose-lowering medication (including insulin) during the VLED and were still obese at the end of the VLED (BMI = 32.3 kg/m2).
Insulin-stimulated glucose disposal improved by ∼100%. This is comparable with the improvements seen in obese non-diabetic patients in whom restrictive bariatric surgery was used to induce weight loss: an increase in M value from 7–19 to ∼35 μmol kgFFM−1 min−1 [29, 30] compared with the increase (from 9.9 ± 2.3 to 37.2 ± 4.6 μmol kgFFM−1 min−1) seen in our patients. In skeletal muscle this increase in insulin-stimulated glucose disposal was reflected in increased insulin signalling at the level of two recently discovered downstream components of PKB/AKT: AS160 and PRAS40, whereas IRS-1-associated PI3K activity showed no difference in absolute levels, although the increase over basal was significant after weight loss. Insulin-stimulated phosphorylation of AS160 is linked to GLUT-4 translocation and has previously been reported to be disturbed in skeletal muscle of moderately obese (BMI = 27 kg/m2) type 2 diabetic patients with relatively mild diabetes . We did not study control individuals and cannot therefore compare insulin-stimulated AS160 phosphorylation in our patients with that of healthy lean individuals. However, our patients were more obese (BMI = 40.2 ± 1.6 kg/m2) and insulin-resistant than the patients in the study mentioned above . Nonetheless, we found that insulin had a significant effect on AS160 phosphorylation on both study days and that weight reduction enhances insulin-stimulated AS160 phosphorylation. To the best of our knowledge these findings have not been described before.
The similar absolute levels of insulin-stimulated IRS-1-associated PI3K activity after weight loss were unexpected in light of the increase of the more distal signalling components, and we have no good explanation for it. It might be, although unlikely , that the timing of the biopsy was such that levels were already declining while those of PRAS40 and AS160 were still rising. Alternatively, there might be no 1:1 relationship between PI3K and AS160 or PRAS40, as was shown for activation of IRS-1 and PI3K . Furthermore, it might be that these were the maximal possible insulin-stimulated PI3K values for this particular patient group (obese type 2 diabetic patients with advanced disease who were still obese at the end of the study), but we did not study a dose–effect curve [4, 20]. Perhaps more likely, given the fact that interventions with thiazolidinediones [31, 32] and exercise  also show discrepancies between improvement of whole-body insulin-stimulated glucose disposal and no effect on PI3K activation, is that there is another activation route of PI3K–PKB/Akt–AS160. Finally, the increase of insulin-stimulated PI3K activity over basal could still have played a role. However, this is unclear from our results and for now we have insufficient arguments for a role of PI3K in the improvement of insulin-stimulated glucose disposal.
Notably, we observed, also for the first time, that weight reduction significantly increases insulin-stimulated PRAS40 phosphorylation, another substrate for PKB/Akt. PRAS40 has been identified as a component of the mammalian target of rapamycin (mTOR) nutrient-sensing pathway, whose activity is deregulated in rodent models of insulin resistance [34, 35]. Although the physiological function of PRAS40 in insulin action is not completely clear, we recently observed that phosphorylation of this protein is induced by physiological hyperinsulinaemia in insulin target tissues, and is blunted under conditions of high fat diet-induced insulin resistance . Whether the improvement in insulin-stimulated PRAS40 phosphorylation also relates to mTOR and whether it can be ascribed to weight loss and/or ER will be the subject of further studies.
Remarkably, the improvement in insulin signalling was not accompanied by a significant improvement in GLUT-4 translocation to the cell membrane. Others have also reported a dissociation between insulin-stimulated glucose disposal and improvement in either insulin signalling and/or GLUT-4 content at the cell membrane. Ryder et al.  found that although insulin-stimulated glucose disposal was 50% lower in patients with type 2 diabetes compared with lean control individuals, insulin-stimulated cell surface GLUT-4 content over basal was only 10% that of healthy controls. In another study, Karlsson et al. found a significant, 36% improvement in insulin-stimulated whole-body glucose uptake after 26 weeks of treatment with rosiglitazone in newly diagnosed type 2 diabetic patients; this change, however, was not accompanied by improved signalling of IRS-1-associated PI3K, PKB/AKT or AS160 . Finally, Friedman et al.  showed that loss of 36% of initial bodyweight by gastric bypass surgery improved whole-body glucose disposal threefold and maximal glucose transport activity in vitro by 50% in three non-diabetic and four type 2 diabetic morbidly obese individuals with no effect on total GLUT-4 protein content in skeletal muscle biopsies. Collectively, these findings indicate that it is not the amount of GLUT-4 at the cell membrane but its function and, consequently, the velocity of glucose transport across the membrane that is quantitatively responsible for insulin-stimulated glucose disposal, as has been described previously . Alternatively, another glucose transporter, either GLUT-1  or a yet unidentified one, may have contributed to the increase in glucose uptake seen after weight loss. Another possible explanation is that insulin-stimulated glucose disposal in adipose tissue is greatly enhanced with weight loss.
It has been hypothesised that accumulation of IMCL metabolites is involved in the impaired insulin signalling via phosphorylation of IRS-1 and IRS-2 on serine residues, thereby rendering these serine-phosphorylated IRSs unable to associate with and activate PI3K . In our study, substantial weight loss was associated with a significant decrease in IMCL, and the amount of IMCL on the day of 50% EWR correlated negatively with the glucose disposal rate. Indeed, other studies also revealed a similar association [30, 40]. Rather than triacylglycerol itself, derivatives such as fatty acyl CoAs and diacylglycerol seem to be the causal factor for the development of insulin resistance . Moreover, there is a potential link between the accumulation of these metabolites and the mitochondrial dysfunction that has been observed in type 2 diabetic patients and their offspring . We did not measure mitochondrial density or ATP production but one expects that after weight loss due to ER, the organism has shifted to fatty acid beta-oxidation rather than to glucose oxidation for muscle ATP production. This may have led to lower fatty acid concentrations in the sarcoplasma and thereby to improved insulin sensitivity. Clearly FAT/CD36 does not seem to be involved in the decrease in IMCL since sarcolemmal FAT/CD36 content did not change with weight loss.
Patients with type 2 diabetes have a decreased percentage of type I (oxidative) muscle fibres and an increased percentage of type IIb (glycolytic) muscle fibres [41, 42]. Weight loss did not result in a significant increase in the percentage of type I muscle fibres in our study, which is consistent with that of all [43, 44, 45] but one other study . Interestingly, like one other study , we also found a negative relationship between the amount of type I muscle fibres on day 2 and time to 50% EWR.
Whether the withdrawal of high doses of insulin has also played a role in the observed improvements in insulin sensitivity of liver, adipose tissue and muscle cannot be deduced from this study. In our short-term (2 day VLED) study we found no arguments for this [16, 17]. A study by Del Prato et al. shows that chronic (72–96 h) physiological hyperinsulinaemia impairs insulin sensitivity of the pancreas and muscle, not of the liver . How long it takes to restore normal insulin sensitivity after cessation of hyperinsulinaemia is unknown. When a VLED and instituting insulin therapy were compared as therapy for type 2 diabetic patients on oral drug failure, both improved glucose levels but only a VLED improved insulin-stimulated glucose disposal . So, it may very well be that the high doses of insulin used by our patients have contributed to their insulin resistance and that the withdrawal of this insulin played a role in the improvement in insulin sensitivity.
In conclusion, short-term energy restriction (2 day VLED) improves hyperglycaemia primarily via a decrease in EGP [16, 17]. Moderate weight reduction (approximately 8 kg) also improves hepatic insulin sensitivity , and substantial weight loss improves all aspects of glucose metabolism (this study). To the best of our knowledge this is the first study to show that weight loss improves insulin signal transduction, especially insulin-stimulated AS160 and PRAS40 phosphorylation. The large increase in insulin sensitivity in patients who were still obese and used no glucose-lowering medication again stresses the importance of weight-reducing approaches in the treatment of obese type 2 diabetic patients.
The authors would like to thank I. Boesten for excellent technical help with GLUT-4 and FAT/CD36 immunoblotting assays; Nutrition & Santé, Antwerp, Belgium for the free supply of Modifast; and Roba Metals (IJsselstein, the Netherlands) for financial support.
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.